Early Data On Amgen’s AMG 133 Show Potential Durability, Dosing Advantage In Obesity
The drug is dosed once every four weeks – compared with Mounjaro and Wegovy’s weekly dosing – but the company also signaled it is considering extended dosing intervals.
You may also be interested in...
Amgen’s obesity drug MariTide will not have Phase II results until late 2024, but the company’s Q4 earnings call was dominated by questions seeking insight about the drug’s potential.
Competing in the obesity market will require significant investment, which Amgen is preparing for, CEO Robert Bradway told investors during the Morgan Stanley Healthcare conference.
With mirikizumab delayed until Lilly overcomes the FDA’s manufacturing concerns, the company has fallen behind on its goal of five approvals in 2023.